Biovica International AB (publ) (BIOVIC-B) - Total Assets
Based on the latest financial reports, Biovica International AB (publ) (BIOVIC-B) holds total assets worth Skr56.82 Million SEK (≈ $6.11 Million USD) as of July 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Biovica International AB (publ) (BIOVIC-B) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Biovica International AB (publ) - Total Assets Trend (2014–2025)
This chart illustrates how Biovica International AB (publ)'s total assets have evolved over time, based on quarterly financial data. See net assets of Biovica International AB (publ) for net asset value and shareholders' equity analysis.
Biovica International AB (publ) - Asset Composition Analysis
Current Asset Composition (April 2025)
Biovica International AB (publ)'s total assets of Skr56.82 Million consist of 47.4% current assets and 52.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 37.6% |
| Accounts Receivable | Skr4.45 Million | 6.9% |
| Inventory | Skr1.93 Million | 3.0% |
| Property, Plant & Equipment | Skr4.77 Million | 7.3% |
| Intangible Assets | Skr26.54 Million | 40.9% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Biovica International AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIOVIC-B company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biovica International AB (publ)'s current assets represent 47.4% of total assets in 2025, an increase from 10.3% in 2014.
- Cash Position: Cash and equivalents constituted 37.6% of total assets in 2025, up from 3.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 12.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 40.9% of total assets.
Biovica International AB (publ) Competitors by Total Assets
Key competitors of Biovica International AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Biovica International AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 3.56 | 22.08 |
| Quick Ratio | 0.80 | 3.47 | 21.99 |
| Cash Ratio | 0.56 | 0.00 | 0.00 |
| Working Capital | Skr-4.12 Million | Skr52.68 Million | Skr156.93 Million |
Biovica International AB (publ) - Advanced Valuation Insights
This section examines the relationship between Biovica International AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.07 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -50.6% |
| Total Assets | Skr64.95 Million |
| Market Capitalization | $14.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biovica International AB (publ)'s assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biovica International AB (publ)'s assets decreased by 50.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biovica International AB (publ) (2014–2025)
The table below shows the annual total assets of Biovica International AB (publ) from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | Skr64.95 Million ≈ $6.99 Million |
-50.57% |
| 2024-04-30 | Skr131.41 Million ≈ $14.14 Million |
-23.73% |
| 2023-04-30 | Skr172.29 Million ≈ $18.54 Million |
+13.62% |
| 2022-04-30 | Skr151.63 Million ≈ $16.32 Million |
-21.29% |
| 2021-04-30 | Skr192.65 Million ≈ $20.73 Million |
+113.44% |
| 2020-04-30 | Skr90.26 Million ≈ $9.71 Million |
+48.31% |
| 2019-04-30 | Skr60.86 Million ≈ $6.55 Million |
-24.65% |
| 2018-04-30 | Skr80.77 Million ≈ $8.69 Million |
-16.89% |
| 2017-04-30 | Skr97.18 Million ≈ $10.46 Million |
+238.23% |
| 2016-04-30 | Skr28.73 Million ≈ $3.09 Million |
+61.78% |
| 2015-04-30 | Skr17.76 Million ≈ $1.91 Million |
+23.43% |
| 2014-04-30 | Skr14.39 Million ≈ $1.55 Million |
-- |
About Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more